The largest drug
discovery company
in the CEE region

More

Your integrated drug
discovery partner of choice

More

Developing breakthrough
therapies in oncology

More

Delivering comprehensive
research solutions to biotech
and pharma

More

News See all

Selvita Reports First Quarter 2019 Financial Results and Provides…

- Investigational New Drug (IND) application to conduct a Phase 1 study of selective CDK8 inhibitor SEL120 cleared by U.S....
More

Selvita announces availability of abstracts regarding Phase 1/2 study…

Krakow, Poland - 16 May 2019 - Selvita today announced that abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for...
More

Selvita to Present at the UBS 2019 Global Healthcare…

Krakow, Poland – 13 May 2019 – Selvita (WSE:SLV), a clinical stage drug discovery and development company engaged in the...
More

Selvita appoints Tom Coulter as Integrated Drug Discovery Director

Krakow, Poland – 09 May 2019 - Selvita, one of the largest providers of drug discovery services in Europe, announced...
More

Poster regarding Phase 1/2 study of SEL24/MEN1703 accepted for…

Krakow, Poland – 17 April 2019 – Selvita today announced that an abstract providing details of the Phase 1/2 study...
More

About Selvita

Selvita has two primary focus areas:

– to serve the drug discovery market as a customer centric provider of high quality, integrated drug discovery services and

– as a drug discovery company engaged in the research and development of breakthrough therapies in oncology.

More

Drug Discovery Services

Selvita is a global integrated drug discovery partner for the pharmaceutical and biotechnology industries.

We offer drug discovery support at every stage of the early discovery phase up to the preclinical research phase.

More

Research and Development

In its internal research and development efforts, Selvita focuses on different dimensions of oncology.

The company’s most advanced R&D program is SEL24, a dual PIM/FLT3 kinase inhibitor currently in Phase I/II clinical study, in acute myeloid leukemia.

More

Investor Relations SLV -1,4000 PLN ( -2,33% )

Share price 2019-05-24 09:37:15

58,6000 PLN More

Careers

We are a multicultural and a multinational company employing professionals from all over the world.

Find out who we’re courrently looking for and what we can offer our employees.

More